Vima Therapeutics

Biotech · Private

Oral selective muscarinic antagonist therapeutic molecule (VIM0423) for neurological disorders

New patent ·
Claim this profile

Follows are private to you and power your alerts

Updated · vimatx.com

Sector
Biotech
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
3
11 pending · first 2025
Rank in peer group#339 of 1449

Capital timeline

No federal awards or Form D filings are on record for this company.

Many early companies raise without filing a Form D, or have not yet won a federal award. New records appear here as the sources update.

Checked: SEC EDGAR Form D through Oct 23, 2026; SBIR and STTR awards through Oct 21, 2026; USAspending contract awards

Founder? Add funding context

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#339 · top 23%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 3 granted of 14
Show all 14 patent records
  • Therapeutic Methods And Compositions For Treating Movement DisordersSep 29, 2026 · US 12,746,231Granted
  • Therapeutic Methods And Compositions For Treating Movement DisordersJun 30, 2026 · US 12,667,562Granted
  • Therapeutic Methods And Compositions For Treating Movement DisordersMay 7, 2026 · Application 19376116Pending
  • Therapeutic Methods And Compositions For Treating Movement DisordersNov 6, 2025 · Application 19092490Pending
  • Therapeutic Methods And Compositions For Treating Movement DisordersMay 6, 2025 · US 12,290,513Granted
  • Therapeutic Methods And Compositions For Treating Movement DisordersApplication 63715318Pending
  • Therapeutic Methods And Compositions For Treating Movement DisordersApplication PCTUS2024027850Pending
  • Therapeutic Methods And Compositions For Treating Movement DisordersApplication 63615960Pending
  • Therapeutic Methods And Compositions For Treating Movement DisordersApplication 63464409Pending
  • Therapeutic Methods And Compositions For Treating Movement DisordersApplication 63715080Pending
  • Therapeutic Methods And Compositions For Treating Movement DisordersApplication PCTUS2025053609Pending
  • Therapeutic Methods And Compositions For Treating Movement DisordersApplication 63813518Pending
  • Therapeutic Methods And Compositions For Treating Movement DisordersApplication 63802953Pending
  • Therapeutic Methods And Compositions For Treating Movement DisordersApplication PCTUS2025053486Pending
  • Revere Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
  • Sienna BiopharmaceuticalsSimilar federal contract value in Biotech · null in contracts
  • ONE-DERINGS LLCSimilar federal contract value in Biotech · null in contracts
  • Triveni BioSimilar federal contract value in Biotech · null in contracts
  • First Light Biosciences Inc.Similar federal contract value in Biotech · null in contracts
  • jCyte, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .